Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion Nets $1.8M NIH Grant

NEW YORK (GenomeWeb News) – Fluxion Biosciences has been awarded a $1.8 million grant from the National Institutes of Health to continue developing high-throughput screening technologies for anti-microbial drug development research, the company said today.

The Phase II grant will continue development of the company’s microfluidic platform for cellular research and drug discovery. The first phase of the project identified a high-throughput screening approach for anti-microbial drugs, and the second phase will focus on integrating the drug screening approach into a fully automated platform, the company said.

The system is based on high-throughput functional screening of live bacteria or cells, and the company expects it may be used in development of drugs for treatment of cardiovascular and immune disorders.

"The results of our Phase I project showed significant gains over conventional drug screening approaches. This platform promises to be a powerful tool for developing the next generation of drug therapies,” Christian Ionescu-Zanetti, Fluxion’s chief technology officer, said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.